Predictive Factors for Antiproliferative Activity of Octreotide LAR in Advanced Neuroendocrine Tumors Abstract #1072

Introduction: The antiproliferative activity of Octreotide LAR in Neuroendocrine Tumors(NETs) has been demonstrated by small retrospective studies and confirmed by a prospective phase III trial(PROMID).However,there are limited data about the duration and predictors of response.
Aim(s): The aim of our retrospective study was to determine the time to radiological progression(TTRP) of disease and the factors that were associated with better response.
Materials and methods: 254 patients with advanced NETs and positive somatostatin receptor scintigraphy were included.Radiological assessment was based on RECIST criteria.Univariate and multivariate analyses were used to identify predictive factors.Median TTRP and 95% confidence intervals were calculated using Kaplan-Meier analysis.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Faidon Laskaratos
Keywords: octreotide LAR, NETs

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1091 IFNα versus IFNα Plus Octreotide LAR in Treatment of NETs
Introduction: It is still unknown whether the combination of IFNα with octreotide LAR has benefit compared with IFNα alone
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Galina Emelianova
#1338 Use of Lanreotide LAR in the Case of Intolerance of Octreotide LAR in Patients Well-differentiated NETs
Introduction: Intolerance of Octreotide is about 10 % of cases
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: prof Vera Gorbunova
#1721 Optimisation of the Size Variation Threshold for CT Evaluation of Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors Treated with Octreotide LAR
Introduction: In advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs), somatostatin analogs treatment rarely achieve a reduction of -30% in the sum of longest diameters (SLD) of target lesions required by Response Evaluation Criteria in Solid Tumors (RECIST) for an ‘objective response’. The implication of Stable Disease (SD) as an additional indicator of therapeutic effect is often uncertain.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Yanji Luo
Authors: Luo Y, Chen J, ...
#2055 Antiproliferative Effect of Above-Label Doses of Somatostatin Analogues (SSA) for the Management of Neuroendocrine Tumors (NETs)
Introduction: Escalated doses of SSA have been used for control of refractory symptoms and tumour growth
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Faidon Laskaratos
Authors: Laskaratos F, Shah R, Banks J, Smith J, ...
#154 Long-term disease stabilization in a patient with advanced pancreatic neuroendocrine tumor treated with combined everolimus and octreotide LAR after prior failure of cytotoxic therapy
Introduction: Targeting of multiple pathways has become an important strategy for improved tumor control in metastatic neuroendocrine tumors (NETs). Among these targets is the mammalian target of rapamycin (mTOR), a central regulator of cell growth, proliferation, and apoptosis, which is blocked by everolimus, an oral inhibitor of mTOR that has shown efficacy in patients with metastatic pancreatic NETs. Recent evidence has suggested that suppression of insulin-like growth factor-1 receptor (IGF-1R) secretion with octreotide therapy, along with concurrent inhibition of mTOR by everolimus, may improve tumor control synergistically by preventing feedback activation of the PI3K/Akt/mTOR pathway.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Alexandre Teulé Vega